RxDoctor Payments Data

Duane Berkompas, MD

Interventional Cardiology · Grand Rapids, MINPI 1174521116

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $112,688 of the $158,847 with a category attached, or 70.9%. Medtronic accounts for 79.5% of it on its own, with 16 other manufacturers making up the rest. Among interventional cardiology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$158,847in general payments, 2019–2025

Across 475 payments — averaging $334.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$126K
  • Abbott$24K
  • Boston Scientific$2K
  • Edwards Lifesciences$2K
  • W. L. Gore & Associates, Inc.$2K
  • Ancora Heart, Inc.$1K
  • plus $798 from 11 others
$177,174in research payments, 2019–2025

Across 60 payments — averaging $2952.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$150K
  • Boston Scientific$27K

What the payments were for

  • Consulting fees$9,1256%
  • Speaking & faculty fees$112,68871%
  • Travel & lodging$24,76916%
  • Food & beverage$12,2658%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,847 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$121,456
Medicare patients
891
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$91,313
XareltoRivaroxaban26$29,732
Metoprolol Succinate107$2,557
Atorvastatin Calcium86$2,012
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$1,388
ClopidogrelClopidogrel Bisulfate61$1,102
Potassium Chloride28$1,032
Carvedilol54$925
Ezetimibe25$603
Rosuvastatin Calcium26$576
Isosorbide Mononitrate ErIsosorbide Mononitrate26$457
Amlodipine Besylate43$426
Spironolactone21$395
Furosemide50$353
Losartan Potassium25$349

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →